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Abstract 
To avoid artefacts introduced by culturing cells for extended periods of time, it is crucial to use low-passage patient-derived tumour cells. 
The ability to enrich, isolate and assay sub-populations of cells that behave as cancer stem cells (CSCs) from these primary cell lines is 
essential before performing characterizations such as gene-expression profiling. We have isolated cells from glioblastomas which show 
characteristics of CSCs. Although glioblastomas contain only a relatively small amount of putative CSCs, these cells express many 
genes which seem to be worthy targets for future therapies. 
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Introduction 
Al-Hajj et al were the first to identify and prospectively isolate a 
minority sub-population of cells from human solid tumours that 
contained all of the in vivo tumour-forming abilities. The 
tumourigenic cell population was identified based on its cell 
surface phenotype. This population could initiate tumours in 
immuno-compromised mice with as few as 200 cells, while as 
many as 500,000 or more of the remaining cells in the tumour 
did not initiate new tumours in mice [1]. 
Fang  et al have shown that upon culturing of metastatic 
melanoma cell suspensions under appropriate conditions, a 
subset of cells could be propagated as non-adherent spheres, 
which could then be induced to differentiate in vitro and to 
generate tumours in vivo [2]. The ability to acutely isolate and 
assay sub-populations of cells from tumours that behave as 
cancer stem cells (CSCs) is essential before performing 
characterizations such as gene-expression profiling, to avoid 
artefacts introduced by culturing cells for extended periods of 
time. 
 
Results 
Tissue samples 
Glioblastoma (GBM) tissues were obtained intra-surgically. A 
trained pathologist evaluated stage and grading of the removed 
tumour tissue. For our experiments, we only cultivated cells 
from tissues containing at least 90% tumour cells as determined 
by H&E staining (Figure1A–C). In a more elaborate diagnosis, 
we determined glial origin (GFAP) (Figure1D), mitotic activity 
(KI-67) (Figure1E) and neoplastic character (MAP2C) 
(Figure1F). 
 
In vitro generation of neurospheres 
Tissues that met our criteria were used for low-passage cell 
culture. We enriched CSCs using embryonic stem (ES) cell 
medium supplemented with FGF2 [3]. Cells cultured under 
these conditions began to change their morphology towards a 
colony-forming phenotype (Figure 2). This phenotype was 
similar to that of hES cells cultured under the same conditions. 
Further analysis showed that the phenotype remained stable for 
at least four weeks and was reversible by FGF withdrawal. 
To show the de-differentiation towards a more primitive neural 
phenotype, we performed immunofluorescence microscopy of 
cells from the normal medium and ES medium with NESTIN. 
Cell sorting 
To investigate if the treated cells were enriched for putative 
cancer stem cells, we employed magnetic sorting with a bead-
coupled anti-CD133 antibody. Enrichment of CSCs by selective 
cell culture methods resulted in higher yields of CD133+ cells 
(Figure 4A). This enrichment was time dependent, with its 
maximum yield after 16 days of stimulation (Figure 4B). 
To determine the quality of enrichment, we kept the cells from 
the positive and negative fractions in culture for four days and 
stained them with a fluorescence coupled anti-CD133 antibody 
(Figure 5).  
Pathway analysis 
To identify the mechanisms and pathways underlying CSCs, we 
conducted RNA-expression analysis using the Illumina platform. 
For expression analysis, we used CD133+, CD133− and bulk 
cells from the GBM1207 cell line and compared this data to the 
expression profile of hES lines H1/H9 (Figure 6). Expression 
analysis revealed a group of 11 genes that were over-
expressed and known to play a role in the progression of 
various malignancies (Figure 7). 
We validated the differential expression of eight selected marker 
genes from the expression analysis by real-time PCR (Figure 
8). All markers were found significantly (>1.5-fold) over-
expressed in CD133+ cells compared to the respective negative 
fraction. 
 
Conclusion 
Still only little is understood about the origin and nature of CSCs 
[4]. From our findings, we conclude that although GBMs contain 
only a relatively small amount of putative CSCs, these cells 
express many genes, which seem to be worthy targets for future 
therapies. Among these genes, we found important signalling 
molecules for angiogenesis, apoptosis, multi-drug resistance 
and metastasis. A large number of markers that have clinical 
relevance for the evaluation of prognosis in various tumours 
show increased expression in CD133+ cells compared to their
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Figure 1: H&E staining of glioblastoma tissues shows typical histological features of the tumour (A–C). In (A), vessel proliferates are present; 
(B) shows an area of extensive necrosis, while (C) displays mitotic cells within the tumour. Immunohistochemical characterization of the 
removed tissue confirms the diagnosis. (D) shows staining against GFAP, a marker for glial origin. (E) KI-67 antibody is used to show the high 
mitotic activity in the tumour tissue. (F) Proof of neoplastic character of the tissue, using an anti-MAP2C antibody. 
 
Figure 2: Phase contrast micrographs from human GBM cells treated with ES-medium + FGF2. Untreated cells cultivated in normal medium 
grew as monolayers. Under ES cell conditions, the cells began to change their morphology and developed a spherical, colony forming 
phenotype. After eight days of cultivation under these conditions the phenotype remained stable and the spheres began to detach from the 
substrate. 
 
 
Figure 3: We stained both, adherent monolayer (A) and colony (B) grown cells against Nestin. Nestin is a type VI intermediate filament, which is 
commonly used as a marker for neuronal precursor cells. Untreated cells do not express Nestin (C), while it was expressed in all spheres (D–F). 
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Figure 4: (A) shows the different yields of CD133− and CD133+ cells after MACS sorting. E(−): negative fraction from ES medium; N(−): negative 
fraction of cells cultured in normal medium; E(+): CD133+ fraction of cells cultured in ES medium; N(+) CD133+ cells isolated from cells grown 
in tumour medium. The yield of CD133+ cells increases upon duration of stimulation. (B) shows the quantification of CD133+ cells after nine 
and 16 days of stimulation in ES medium. 
 
Figure 5: CD133+ and CD133− cells were stained for CD133 expression. The negative fraction (A) showed no CD133 expression, while the 
majority of cells from the CD133 positive fraction had strong expression of the protein (B–D). DAPI inset. 
 
Figure 6: (A) Cluster analysis of expression profiling from GBM1207 bulk, CD133+ and CD133− cells. (B) GO- and KEGG analysis of CD133+ 
revealed a set of activated pathways, known to be important for oncogenesis. Although most tumours harbour only a small subset of CSCs, 
these cells might have a high impact on the properties of the tumour. Red arrows mark pathways, which came up in the analysis of CD133+ 
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cells and hES cells. (C) Comparison of CD133+/− fraction with human ES cells. The negative fraction shares only 11 genes with hES cells, while 
61 genes are expressed exclusively in CD133+ and ES cells. From these 61 candidates, 46 are known to play a role in various cancers and eight 
targets are most commonly expressed in hES cells. These 61 genes could provide the basis for the identification of new CSC markers and 
future drugs. 
 
Figure 7: Among the differentially expressed genes that are shared between CD133+ and hES cells, common regulators of oncogenisis and 
markers for prognosis were identified. These proteins cover a variety of properties, which include angiogenesis, inhibition of apoptosis, multi-
drug resistance and cell-cycle control proteins. 
 
Figure 8: Real-time validation of eight candidate genes identified by genome-wide expression profiling. The relative over-expression of these 
genes indicates that CSCs despite their rare distribution in the tumour tissue might have a strong influence on the descended cells. The over-
expression of genes like VEGF point to the fundamental role CSCs might have on the establishment and maintenance of a tumour promoting 
micro-environment or niche. Other genes like CK2 function as interfaces in a plethora of cancer relevant pathways such as p53, wnt-signalling 
and Ç-catenin. 
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CD133− counterparts. Additionally, these CD133+ cells share 
important pathways with human ES cells, which help explaining 
self-renewal capacity, drug-resistance and other properties 
credited to stem cells and cancer. 
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